Abstract:Introduction: Coronary microvascular dysfunction (CMD) is characterized by impaired endothelial-dependent vasodilation. These impairments are seen in diabetic cardiomyopathy, ischemia with no obstructive coronary artery disease, and heart failure with preserved ejection fraction (HFpEF), but detailed mechanisms have yet to be elucidated. Sirtuin 6 (Sirt6), an important member of the Sirtuin family, has been implicated in obesity, insulin resistance, type 2 diabetes mellitus (T2DM), and cardiovascular diseases. Sirt6 protects EC from premature senescence, oxidative stress, and atherosclerosis by sustaining high eNOS levels and preserving cell replication. Sirt6 was reported to regulate endothelial dilation in atherosclerosis in Sirt6 heterozygous mice, but how Sirt6 regulates coronary microvascular function remains to be determined. Methods: Sirt6 knockout and wild-type (WT) mice were fed a diet high in fat and sugar (HFHS) for six months, and blood lipid and glucose were measured. Coronary arteries were isolated, and endothelial-dependent vasodilation (EDD) was assessed using myography (DMT). Echocardiography and treadmill exercise exertion tests were performed to evaluate cardiac function. Myocardial blood flow (MBF) was measured by doppler. Cardiac fibrosis was detected using trichrome staining, and molecular pathways were elucidated via gene and protein analysis. Results: Our preliminary data show that Sirt6 was downregulated in diabetes. The EDD of coronary arterioles was impaired, and the mediator of coronary vasodilation switched from NO to H 2 O 2 in the Sirt6 knockout mice. Compared to the WT mice, myocardial blood flow is decreased, ejection fraction (EF) was not changed, the running distance was reduced, and E/E’ ratio was increased in Sirt6 knockout mice. The Sirt6 targeted proteins were identified. Conclusions: Sirt6 regulated coronary microvascular function, and ablation of Sirt6 caused CMD and diastolic dysfunction. Further genetic profiling will elucidate the pathways and mechanisms converging with Sirt6 to regulate microvascular function.

Hepatocyte-specific Sirt6 Deficiency Impairs Ketogenesis.

SIRT6 Suppresses Mitochondrial Defects and Cell Death Via the NF-κB Pathway in Myocardial Hypoxia/reoxygenation Induced Injury.

SIRT6 Controls Hepatic Lipogenesis by Suppressing LXR, ChREBP, and SREBP1.

Hepatic-Specific Disruption of Sirt6 in Mice Results in Fatty Liver Formation Due to Enhanced Glycolysis and Triglyceride Synthesis

Sirtuin 6—A Key Regulator of Hepatic Lipid Metabolism and Liver Health

Fat-Specific Sirt6 Ablation Sensitizes Mice to High-Fat Diet–Induced Obesity and Insulin Resistance by Inhibiting Lipolysis

Liver-specific Sirtuin6 Ablation Impairs Liver Regeneration after 2/3 Partial Hepatectomy.

SIRT6 Protects Against Liver Fibrosis by Deacetylation and Suppression of SMAD3 in Hepatic Stellate Cells

SIRT6 Protects Against Liver Fibrosis by Deacetylation and Suppression of SMAD3 in Hepatic Stellate CellsSummary

Impaired reciprocal regulation between SIRT6 and TGF- signaling in fatty liver

Impaired reciprocal regulation between SIRT6 and TGF‐β signaling in fatty liver

Hepatic SIRT6 Deficit Promotes Liver Tumorigenesis in the Mice Models

[The role of SIRT6 in nonalcoholic steatohepatitis]

SIRT6 Regulates Metabolic Homeostasis in Skeletal Muscle Through Activation of AMPK.

SIRT6 regulates SREBP1c-induced glucolipid metabolism in liver and pancreas via the AMPKα-mTORC1 pathway

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

SIRT6 Regulates Obesity-Induced Oxidative Stress Via ENDOG/SOD2 Signaling in the Heart.

Lack of SIRT1 (mammalian Sirtuin 1) Activity Leads to Liver Steatosis in the SIRT1+/- Mice: a Role of Lipid Mobilization and Inflammation.

Sirt6 Deficiency Results in Severe Hypoglycemia by Enhancing Both Basal and Insulin-Stimulated Glucose Uptake in Mice

The Role of Sirt6 in Obesity and Diabetes

Abstract P3138: The Regulatory Role Of Sirtuin 6 In Coronary Microvascular Dysfunction